Aneta Zachova is a journalist at Eurasia Review. She focuses on health and wellness, with a particular emphasis on medicine, healthcare, and healthcare systems. Aneta's work has been featured in LRT and EURACTIV.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Czech Republic (National)
Not enough data
Aneta Zachova's coverage focuses on government announcements and legal policy regulations, specifically in the context of the Czech Republic and its relations with other countries. She covers topics related to politics, migration, and international relations at both national and European levels.
If you are considering reaching out to Aneta with a pitch or as a potential source, ensure that your content is closely aligned with political developments within the Czech Republic or EU affairs. Expert commentary on government policies, legal regulations, or geopolitical events would likely be well received by her based on her coverage attributes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Czech patient advocate warn that ongoing EU negotiations risk rolling back decades of progress in patient involvement
The new government's coalition agreement positions Czechia as a sovereignty-focused actor in Brussels
Responsibility was claimed in emails to Czech media by a previously unknown group calling itself The Earthquake Faction
The Babiš government's decision could reduce already low immunisation rates, warn health experts
Poland's vaccination drive gains momentum amid uneven progress and persistent gaps
Press freedom watchdogs warn of parallels with Slovakia and Hungary as tensions with independent media escalate
By: Aneta Zachová
At the centre of the dispute lie the post-war laws authorising the expulsion of around three million ethnic Germans from Czechoslovakia after 1945
Prague's longstanding pro-Israel stance comes as several EU governments push for a tougher line on Benjamin Netanyahu
EU Health Commissioner Várhelyi described the state-of-the-art cancer centre as a potential model for Europe
Analysis shows Czech patients now wait an average of 659 days for innovative therapies after they are approved at EU level
